Rumors have resurfaced that Novartis is looking to shift some of its eye drugs but the Basle-based behemoth tells Scrip it remains committed to in-market products and R&D projects in the ophthalmology space.

Just over a month after raising $97m in a series B round, Oxford University spinout MiroBio and its immune checkpoint agonists have been snapped up by Gilead Sciences. 

Looking to take advantage of the cool reception private biotechs are receiving from the public markets, a leading European VC is targeting investments of up to €70m per deal in firms with undervalued late-stage assets.

Cambridge Innovation Capital partner Robert Tansley tells Scrip that the UK has "a really strong history of innovation in biological sciences and Cambridge has been at the forefront” but this has not equated to a substantial number of biotech companies “where we have lagged significantly behind the US."